Jersey Mike's prices at $23 ahead of its NYSE debut — no retail window verified
Jersey Mike's has priced its roughly $1 billion IPO at $23 ahead of its expected NYSE debut, but no mainstream retail allocation window is publicly verified; NASN TECH is the live Hong Kong subscription.
Today's spotlight: Jersey Mike's prices at $23 ahead of its NYSE debut
Status: Priced at $23.00; expected to begin trading on the NYSE on July 30 under JMKE. The offering is expected to close July 31. The issuer has not published a mainstream retail allocation channel. 1 2
Price: $23.00 final offer price
Minimum buy-in: No verified IPO allocation
Broker access: No public allocation was verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull
Jersey Mike's is a fast-casual restaurant franchisor with more than 3,300 locations across the United States and Canada. The retail hook is easy to understand: this is a familiar consumer brand, and the deal is sized at roughly $1 billion. 1
The operating number to keep in view is $4.3 billion in systemwide sales as of the first quarter of 2026. The filing also reports $1.4 million in average unit volume, 50% cumulative same-store sales growth from 2020 through 2025, and more than 12 million active loyalty customers. Those numbers describe the restaurant network, not the return a new shareholder will earn. 3
The offering structure is the first risk check. Jersey Mike's is issuing 13.78 million shares, while existing stockholders are selling roughly 29.7 million more. The company says it will receive no proceeds from the selling-stockholder block; its own proceeds are intended for debt repayment and general corporate purposes. In plain English, most of the headline share count is an early-holder exit, not new cash for expansion. 1
The practical read: a July 30 debut lets investors watch JMKE in the public market, but it does not mean an IPO order was available in a retail app. Wait for a final prospectus and a broker-specific allocation notice before treating any order window as real. A first-day market order is secondary-market trading.
Actionable now
No publicly verifiable mainstream-broker IPO allocation was found open or closing within the 48-hour window around July 30. The public calendar shows JMKE and Reformation as priced deals and Apnimed as an upcoming deal, but it does not establish that a customer can request IPO shares through a named retail broker. 2
| Ticker | Price range | Minimum buy-in | Deadline | Verified brokers | Status |
|---|---|---|---|---|---|
| None verified | Not available | Not available | No public window found | None publicly verified | Watch only |
Market pulse
- About 68% of the offered shares are secondary. That split matters because selling stockholders receive the proceeds from their shares, while the company receives cash only from its 13.78 million newly issued shares. 1
- The next dated healthcare deal has a real regulatory catalyst. Apnimed is offering 10 million shares at $14-$16 and is expected to trade July 31. Its filing says the FDA accepted the Oxnimbi sleep-apnea drug application for review in July, with a February 28, 2027 PDUFA goal date. The same filing warns that approval and the clinical interpretation remain uncertain. 4 5
HK desk
Open now: NASN TECH (2261) is accepting Hong Kong public applications from July 30 through noon on August 4, which converts to August 4 at 04:00 in the channel's display timezone. The offer range is HK$10.42-HK$11.18, the board lot is 100 shares, and ET Net's live IPO dashboard lists an estimated maximum admission amount of HK$1,129.27. Listing is scheduled for August 7. 6 7
NASN TECH develops brake-by-wire systems for intelligent-driving vehicles. ET Net says it had 203 registered patents as of July 21 and that 50% of expected net proceeds would go to research and development. This is a Hong Kong public offer, not a US retail-broker allocation. 6
Closed, but worth tracking: Zhongji InnoLight (3308) opened at HK$971 on its first trading day, below its HK$980 offer price. ET Net also reports that one lot was distributed for every 16 lots subscribed. That is a debut result, not a live subscription. 8
On the radar
| Name | Expected pricing | Expected listing | Terms | Why watch |
|---|---|---|---|---|
| Apnimed (APMD) | July 30, expected | July 31 | $14-$16; 10 million shares; $150 million | Oral sleep-apnea drug candidate with an FDA review milestone, but approval and single-product risks. 4 5 |
| Attovia Therapeutics (ATTO) | August 4, expected | August 5 | $15-$17; 12.5 million shares; $200 million | Phase 1 biotech with no products on the market; the early clinical stage is the main risk and the reason to watch. 9 |
July 30 is a regular NYSE trading day under the 2026 holiday calendar. The useful distinction remains simple: an IPO allocation requires a real order window; a ticker appearing on an exchange is just a public-market listing. 10
This is market information, not investment advice. US calendar coverage uses SEC filings and public IPO calendars; Hong Kong coverage uses ET Net's accessible prospectus-derived pages, so its broker availability is not independently verified.
Related content
- Sign in to comment.
More from this channel
- Apnimed prices at $16 for its Nasdaq debut today — no retail allocation verified
- Reformation hits pricing day, but retail IPO access is still unverified
- IPO action brief: IOND starts trading, but there is no retail window
- IPO action brief: Jersey Mike's enters pricing week, but no retail window
- IPO Action Brief: SCTX prices at $15, but retail access is still unverified